Editorial · 28 Mar 2022
PerspectivePublished 28 Mar 2022
To Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management
Keywords
Subjects
Pharmaceutical SciencesSimilar by topic
Review article · 3 May 2019
SMN2 Gene Based Treatments In Spinal Muscular Atrophy- A Review Of Recent Advancements
Conference abstract · 1 Apr 2019
Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)
Research article · 22 Nov 2017
Assessment of HAART Clinical Outcomes and Associated Direct Costs in a Cohort of Patients Receiving Treatment at a Tertiary Healthcare Facility in North Central Nigeria
Commentary · 1 Jul 2026
Precision Splice-Modulating Antisense Oligonucleotide Strategy for Spinal Muscular Atrophy Type II Functional Recovery Assessment
More from this journal
The newest in Pharmacoeconomics: Open Access.
Opinion · 1 Dec 2025
Drug Repurposing: Economic Gains, Faster Pathways, Rare Diseases
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Patrich J. Welch”

